Summary
The aim of the study was to compare the antihypertensive efficacy and safety of a new beta blocker with high beta1 selectivity, bisoprolol, with captopril in 28 elderly patients, aged over 65 years, with mild-to-moderate essential hypertension (WHO classes I and II). After a placebo run-in period of 4 weeks, the patients were randomly allocated to receive bisoprolol (5 mg od) or captopril (25 mg bid) doubledummy technique) for 6 weeks, according to a crossover double-blind design, with a 4-week washout period between the two active treatments. The doses were doubled after 2 weeks if the supine blood pressure was >160/95 mmHg. In basal conditions and after 2, 4, and 6 weeks of each treatment, the blood pressure and heart rate were assessed both in the supine and erect positions. At the same time, the side effects and quality of life were investigated by a checklist and a selfassessment questionnaire. Standard laboratory tests and a resting ECG tracing were performed before and after each active treatment. The data from 24 patients (4 dropouts) showed a significant antihypertensive effect of both treatments (p<0.01) with a reduction of diastolic blood pressure to values ≤95 mmHg in 75% (18/24) of the patients treated with bisoprolol and in 83.3% (20/24) of those treated with captopril, without significant differences between the two drugs. Bisoprolol also produces a marked but symptom-free reduction of heart rate compared with captopril (p<0.05). Neither the beta blocker nor the ACE inhibitor caused important side effects or worsening of the patients' quality of life, and no changes in laboratory tests and ECG tracings were observed. In conclusion, bisoprolol demonstrated antihypertensive action and tolerability comparable with captopril, and it is a suitable treatment in elderly hypertensive patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arterial Hypertension. Report of a WHO Expert Committee, Technical Report Series. World Health Organization, Geneva, 1978:628.
The 1988 Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure.Arch Intern Med 1988;148:1023–1038.
Bühler FR. Antihypertensive action of β-blockers. In: Laragh DH, Bühler FR, Seldin DW, eds.Frontiers in Hypertension Research. New York: Springer-Verlag, 1981: 423–435.
The IPPSH Collaborative Group. Cardiovascular risk factors in a randomized trial of treatment based on the beta blocker oxprenolol: The International Prospective Primary Prevention Study in Hypertension (IPPSH).J Hypertens 1985;3:379–392.
Decalmer PBS, Chatterjee SS, Cruicksmank JM, et al. Beta-blockers and asthma.Br Med J 1978;40:184–189.
Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Adverse reaction to bendrofluazide and propanolol for the treatment of mild hypertension.Lancet 1981;2:539–543.
Ruckshank JM. The clinical importance of cardioselectivity and lipophilicity in beta-blockers.Am Heart J 1980;100:160–178.
Floras JS, Jones JV, Fox P, et al. The effect of long-term, once-daily administration of atenolol on the blood pressure of hypertensive subjects.J Cardiorasc Pharmacol 1981;3:958–964.
Scott AK, Rigby JW, Webster J, et al. Atenolol and metoprolol once daily in hypertension.Br Med J 1982;284:1514–1516.
Schliep H-J, Harting J. β1-selectivity of bisoprolol, a new β-adrenoceptor antagonist, in anesthetized dogs and guinea pigs.J Cardiovasc Pharmacol 1984;6:1156–1160.
Leopold G, Pabst J, Winkler H, et al. Pharmacokinetics of bisoprolol, a new highly selective β1-selective adrenoceptor antagonist.J Clin Pharmacol 1986;26:616–621.
Weiner L, Frithz G. Antihypertensive effects of bisoprolol during once daily administration in patients with essential hypertension.Eur J Clin Pharmacol 1986;29:517–521.
Bühler FR, Berglund G, Anderson OK, et al. Double-blind comparison of the cardioselective β-blockers bisoprolol and atenolol in hypertension: The bisoprolol international multicenter study (BIMS).J Cardiorase Pharmacol 1986;8 (Suppl 11):S122–S127.
Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after administration in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: A randomized, multicentre double blind study (BISOMET).Eur Heart J 1987:8 (Suppl M):103–113.
Frithz G, Weiner L. Long-term effects of bisoprolol on blood pressure, serum lipids, and HDL-cholesterol in patients with essential hypertension.J Cardiovasc Pharmacol 1986; 8 (Suppl 11):S134–S138.
The European Working Party. Mortality and morbidity results from the European Working Party on high blood pressure in the elderly trial.Lancet 1985;1:1349–1354.
Amery A, Birkenhager W, Brixko P, et al. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. EWPHE results—subgroup analysis based on entry stratification.J Hypertens 1986;4 (Suppl 6):S642–S647.
Groel JT, Tadros SS, Dreslinsky GR, et al. Long term antihypertensive therapy with captopril.Hypertension 1983;5 (Suppl III):III145–III151.
Bulpitt CJ. Quality of life in hypertensive patients. In: Amery A, Fagard R, Lijnen P, Staessen J, eds.Hypertensive Cardiovascular Disease: Pathophysiology and Treatment. The Hague: Martinus Nijhoff, 1982:929–948.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bracchetti, D., Gradnik, R., Alberti, A. et al. A double-blind comparison of bisoprolol and captopril for treatment of essential hypertension in the elderly. Cardiovasc Drug Ther 4, 261–264 (1990). https://doi.org/10.1007/BF01857642
Issue Date:
DOI: https://doi.org/10.1007/BF01857642